Free Trial
NASDAQ:DNTH

Dianthus Therapeutics Q3 2023 Earnings Report

Dianthus Therapeutics logo
$18.76 -0.39 (-2.04%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$18.81 +0.05 (+0.27%)
As of 08/8/2025 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dianthus Therapeutics EPS Results

Actual EPS
-$3.78
Consensus EPS
-$0.51
Beat/Miss
Missed by -$3.27
One Year Ago EPS
N/A

Dianthus Therapeutics Revenue Results

Actual Revenue
$0.92 million
Expected Revenue
$0.50 million
Beat/Miss
Beat by +$420.00 thousand
YoY Revenue Growth
N/A

Dianthus Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Thursday, November 9, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Dianthus Therapeutics' Q3 2025 earnings is scheduled for Thursday, August 14, 2025

Earnings Documents

Dianthus Therapeutics Earnings Headlines

One stock to replace Nvidia
Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.
See More Dianthus Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dianthus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dianthus Therapeutics and other key companies, straight to your email.

About Dianthus Therapeutics

Dianthus Therapeutics (NASDAQ:DNTH), a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

View Dianthus Therapeutics Profile

More Earnings Resources from MarketBeat